Literature DB >> 9951894

Squamous cell carcinoma of the thoracic esophagus following radiation therapy for breast cancer.

G Perrier1, P Teniere, Y Graoc, M Scotte, I Leblanc-Louvry, F Michot.   

Abstract

Between 1981 and 1995, 4 patients (3 females, 1 male; aged 48-80) were diagnosed with squamous cell carcinoma of the esophagus, following mediastinal irradiation for breast cancer. The interval between irradiation and the presentation of esophageal cancer was 10.75 years on average (7-19). The treatment consisted of: radiotherapy only; a partial esophagectomy with proximal gastrectomy without post-operative radiotherapy; laser photocoagulation for a superficial tumor; and, palliative treatment including gastrostomy, tracheal photocoagulation and chemotherapy for 1 patient suffering from advanced stage cancer with tracheal invasion, respectively. Radiotherapy of the esophageal cancer (exclusive or adjuvant) should take into account previous esophageal radiation therapy. The indications of curative excision surgery are the same as for other types of esophageal cancer, but the anastomoses should be performed in a non-irradiated area. Excision by esophageal stripping without thoracotomy is contraindicated because of the presence of peri-esophageal sclerosis. Preventive measures in radiation therapy for breast cancer are suggested.

Entities:  

Mesh:

Year:  1998        PMID: 9951894

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  2 in total

1.  Solitary esophageal metastasis of breast cancer after 11 years: a case report.

Authors:  Mustafa Erman; Aziz Karaoğlu; Berna Oksüzoğlu; Ustün Aydingöz; Ayşe Ayhan; Nilüfer Güler
Journal:  Med Oncol       Date:  2002       Impact factor: 3.064

Review 2.  A patient with tracheoesophageal fistula and esophageal cancer after radiotherapy.

Authors:  Jeroen Hagendoorn; Marguerite E I Schipper; Arjan Cloïn; Faiz Z Ramjankhan; Peter D Siersema; Richard van Hillegersberg
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-11-09       Impact factor: 46.802

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.